research & development

Solving the Solubility Problem in Pharma & Nutraceuticals

At Eve Health Group, research and development is the engine that drives our mission to improve how therapeutic compounds are delivered and absorbed. Following the acquisition of Nextract, our R&D efforts now focus on advanced pharmaceutical delivery systems - underpinned by proprietary solubility and nanoemulsion technologies that improve bioavailability, stability, and patient adherence.
research & development

Our Technology Focus

Our core IP targets the single biggest challenge in oral drug delivery: poor water solubility. Over 40% of approved drugs - and over 90% of development-stage compounds - suffer from bioavailability issues related to solubility. Our solution? A patented, multi-phase solubility enhancement and delivery system that allows active compounds to be more rapidly absorbed by the body - in formats consumers actually want to use.

Key R&D focus areas:
‍
-Nanoemulsion systems for oil- and water-soluble actives
-Controlled-release functional gummies
-Thermally stable delivery formats (for OTC products)
-Dual-phase carrier systems for combination compounds
-Drug reformulation for enhanced absorption (e.g. Tadalafil)
research & development

Our R&D Team Partners

Our scientific leadership includes researchers with decades of experience in pharmaceutical formulation, solubility chemistry, nutraceutical development, and regulatory affairs.
research & development

Commercial & Regulatory Pathway

Our R&D does not stop at discovery - it’s designed for delivery. All research is tied to a clear commercial pathway, whether through direct sales, licensing, or co-development with pharma partners.

Current focus:

-TGA approval of Dyspro and Libbo+
-Licensing solubility IP for repurposed drug applications
-Manufacturing oral strips/softgel/gummy production through GMP-certified facilities
ASX Announcements
ASX Share Price
EVE Price Today by TradingView
Contact Us
Subscribe to our mailing list
Thanks for subscribing!
Something went wrong with the submission.
© EVE Health Group Ltd 2025